Compare CRC & STVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CRC | STVN |
|---|---|---|
| Founded | 2014 | 1949 |
| Country | United States | Italy |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Containers/Packaging |
| Sector | Energy | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.2B | 7.4B |
| IPO Year | N/A | 2021 |
| Metric | CRC | STVN |
|---|---|---|
| Price | $43.91 | $20.60 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 10 | 2 |
| Target Price | ★ $63.70 | $23.75 |
| AVG Volume (30 Days) | ★ 937.9K | 274.8K |
| Earning Date | 11-04-2025 | 11-06-2025 |
| Dividend Yield | ★ 3.68% | 0.30% |
| EPS Growth | N/A | ★ 19.61 |
| EPS | ★ 4.29 | 0.60 |
| Revenue | ★ $3,505,000,000.00 | $1,373,219,524.00 |
| Revenue This Year | $20.33 | $8.42 |
| Revenue Next Year | N/A | $8.77 |
| P/E Ratio | ★ $10.26 | $35.05 |
| Revenue Growth | ★ 34.91 | 6.97 |
| 52 Week Low | $30.97 | $17.81 |
| 52 Week High | $58.41 | $28.00 |
| Indicator | CRC | STVN |
|---|---|---|
| Relative Strength Index (RSI) | 35.53 | 40.99 |
| Support Level | $43.25 | $20.25 |
| Resistance Level | $44.38 | $21.10 |
| Average True Range (ATR) | 1.30 | 0.85 |
| MACD | -0.27 | 0.04 |
| Stochastic Oscillator | 11.39 | 22.19 |
California Resources Corp is an independent oil and natural gas exploration and production company operating properties exclusively within California. It provides affordable and reliable energy in a safe and responsible manner, to support and enhance the quality of life of Californians and the local communities in which the company operates. It has some of the lowest carbon intensity production in the United States and is focused on maximizing the value of its land, mineral, and technical resources for decarbonization by developing carbon capture and storage (CCS) and other emissions-reducing projects.
Stevanato Group SpA is a provider of drug containment, drug delivery and diagnostic solutions to the pharmaceutical, biotechnology and life sciences industries. It delivers an integrated, end-to-end portfolio of products, processes, and services that address customer needs across the entire drug life cycle including development, clinical, and commercial stages. It has two segments; Biopharmaceutical and Diagnostic Solutions which generates key revenue, includes all the products, processes and services developed and provided for the containment and delivery of pharmaceutical and biotechnology drugs and reagents, as well as the production of diagnostic consumables and its other segment is Engineering. Geographically, the company derives majority revenue from Europe, Middle East and Africa.